UBS lowered the firm’s price target on C4 Therapeutics to $20 from $22 and keeps a Buy rating on the shares. C4 has been in a period of execution since the ‘7455 initial data last April, and some fruits of this labor should be seen in 2H with two key pipeline readouts, the full dose escalation data for CFT7455 and Phase 1 dose escalation data for CFT8634, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CCCC:
- C4 Therapeutics announces inducement grants under Nasdaq listing rule
- C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- C4 Therapeutics’ FDA clearance of CFT8919 IND as expected, says Brookline
- C4 Therapeutics Explodes Higher on Lung Cancer News
- C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavailable BiDAC™ Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer